Aging Baby Boomers

1.78k followers • 12 symbols Watchlist by Yahoo Finance

This basket consists of stocks that benefit from the needs of aging baby boomers.

12 symbols

Zacks
Is Fidelity High Dividend ETF (FDVV) a Strong ETF Right Now?
Smart Beta ETF report for FDVV
Zacks
FDA Warns About Safety of Breast Implant: 3 Stocks at Risk
As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.
Zacks
3 Large-Cap Dividend Stocks to Buy After Fed Cuts Interest Rates for Second Time
We searched, using our Zacks Stock Screener, for large-cap dividend stocks investors might want to buy after the U.S. Federal Reserve cut interest rates for the second time...
Zacks
Leisure & Recreation Services Industry Prospects Look Dim
Leisure & Recreation Services Industry Prospects Look Dim
Zacks
Procter & Gamble (PG) Outpaces Stock Market Gains: What You Should Know
Procter & Gamble (PG) closed the most recent trading day at $121.13, moving +1.15% from the previous trading session.
Market Realist
Google’s YouTube: Another Round of Advertiser Boycotts?
A BBC investigation recently discovered dozens of YouTube videos promoting fake cancer cures. Could Google's YouTube lose advertisers?
Zacks
Cruise Stocks in Choppy Waters After Crude Oil Price Rise?
Most of the cruise operators are bearing the brunt of high expenses for quite some time. Increase in oil prices will further elevate their expenses.
Zacks
Are Investors Undervaluing Matthews International (MATW) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Here's How Cigna (CI) is Poised Amid Political Uncertainty
Growth in health services, government business and international markets drive Cigna's (CI) stock.
Market Realist
Procter & Gamble Stock: Valuation Limits Upside
Procter & Gamble stock trades at 24.7x its fiscal 2020 estimated core EPS of $4.85. The stock trades at 23.2x its fiscal 2021 estimated core EPS of $5.17.
Zacks
Allergan (AGN) Dips More Than Broader Markets: What You Should Know
Allergan (AGN) closed at $165.56 in the latest trading session, marking a -0.35% move from the prior day.
Zacks
UnitedHealth Group (UNH) Gains As Market Dips: What You Should Know
UnitedHealth Group (UNH) closed the most recent trading day at $234.43, moving +0.35% from the previous trading session.
Market Realist
Church & Dwight Stock: Valuation Overshadows Growth
Church & Dwight (CHD) stock has risen 9.5% on a YTD (year-to-date) basis as of September 13. However, the stock lags its peers by a wide margin.
Yahoo Finance
Startup uses remittances to remove 'time and distance' from health care
Hoy Health launched less than two years ago, but sees strong growth potential in paving the way to the Latin American health care market.
Zacks
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Reuters
Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan
About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's planned $63 billion purchase of Botox maker Allergan Plc . The combination of two of the world's biggest pharmaceutical companies, which was announced in June, would feature a portfolio that includes the world's top-selling medicine - AbbVie's rheumatoid arthritis drug Humira - as well as its cancer drugs and Allergan's blockbuster wrinkle treatment, Botox, and big-selling dry eye drug Restasis.
Zacks
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb
Zacks
Could the Trade War be Bullish for Stocks?
Tariffs, tweets, negotiations, the Fed cutting rates, full employment, a manufacturing slowdown: how investors can cut through the noise.
Zacks
The Zacks Analyst Blog Highlights: Microsoft, Merck, Procter & Gamble, United Technologies and Coca-Cola
The Zacks Analyst Blog Highlights: Microsoft, Merck, Procter & Gamble, United Technologies and Coca-Cola
Zacks
Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe
The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
Zacks
Allergan (AGN) Outpaces Stock Market Gains: What You Should Know
Allergan (AGN) closed the most recent trading day at $164, moving +1% from the previous trading session.
Zacks
UnitedHealth Group (UNH) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, UnitedHealth Group (UNH) closed at $232.46, marking a +0.77% move from the previous day.
Zacks
Here's Why Procter & Gamble Stock is Worth Betting on Now
Procter & Gamble's (PG) focus on improving its product portfolio through strategic initiatives bodes well. Also, the company is on track with its cost-saving plans.